Moderna Inc said on Wednesday it will ask regulators to authorize its Covid-19 vaccine in children younger than 6 years old based on data showing it generated a similar immune response to adults in its clinical trial.

The Omicron variant of Covid-19 was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38 percent effective in...